Exelixis to Release Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 10, 2021Business Wire • 01/27/21
Exelixis Announces Initiation of Phase 1 Trial Evaluating XL102 as a Single Agent and in Combination with Other Anti-Cancer Agents in Patients with Advanced or Metastatic Solid TumorsBusiness Wire • 01/25/21
Exelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCCThe Motley Fool • 01/23/21
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell CarcinomaBusiness Wire • 01/22/21
Exelixis, Inc. (EXEL) Management Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/12/21
Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021Business Wire • 01/10/21
Exelixis to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021Business Wire • 01/04/21
Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid CancerBusiness Wire • 12/21/20
Exelixis In-Licenses Aurigene's Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid TumorsBusiness Wire • 12/07/20
Exelixis In-Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug ApplicationBusiness Wire • 12/02/20
Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Evercore ISI 3rd Annual HealthCONx (Transcript)Seeking Alpha • 12/01/20
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic TherapyBusiness Wire • 11/27/20